Table 1.
Results | |
Men | 72 (66.1) |
Age (years) | 66 (48-75) |
Length of stay in the ICU (days) | 21 (12.75-31) |
Length of stay in the hospital (days) | 32 (20-53.5) |
APACHE II | 25 (20-32) |
SOFA at ICU admission | 9 (6-12) |
SOFA at the beginning of colistin treatment | 8 (6-11) |
Associated use of vancomycin | 35 (32.11) |
Associated use of amphotericin B | 5 (4.59) |
Associated use of aminoglycoside | 5 (4.59) |
Associated use of diuretics | 38 (34.86) |
Associated use of vasopressors | 73 (66.97) |
Mechanical ventilation | 105 (96.33) |
Treatment duration (days) | 10 (5-15) |
Empirical beginning of treatment | 79 (72.48) |
Concordance with positive cultures (n=79) | 58 (73.42) |
Days since the beginning of treatment | 10 (6-14.25) |
Creatinine at ICU admission (mg/dl) | 1.25 (0.93-2.11) |
Creatinine at the beginning of treatment (mg/dl) | 1.49 (0.90-2.29) |
Acute kidney injury | |
Patients on hemodialysis before treatment | 29 (26.61) |
Patients not on hemodialysis before treatment (n=80) | |
Absence of acute kidney injury | 59 (73.75) |
Presence of acute kidney injury | 21 (26.25) |
All-cause hospital mortality | 91 (83.49) |
All-cause 30-day mortality | 78 (71.56) |
ICU - intensive care unit; APACHE II - Acute Physiology and Chronic Health Evaluation II; SOFA - Sequential Organ Failure Assessment. Results expressed as number (%) or median (25%-75%).